S-octylglutathione

Summary

S‑octylglutathione (also called GS‑8, GSO8, or octyl‑GSH) is a synthetic analogue of the tripeptide glutathione in which the cysteine thiol is alkylated with an octyl chain. In research, it is employed primarily as a competitive inhibitor of glutathione S‑transferases (GSTs) and related enzymes such as glyoxalase I. By blocking GST activity, it helps investigators probe the role of these detoxifying enzymes in lipid peroxidation, xenobiotic metabolism, and the biotransformation of specialized compounds like the explosive CL‑20.

Mechanism of Action

S‑octylglutathione binds to the active site of GSTs, occupying the glutathione‑binding pocket and preventing the natural substrate from accessing the catalytic residues. Calorimetric and crystallographic studies show a single molecule per dimer (or two for shorter alkyl analogues) with affinity increasing with alkyl chain length, indicating a hydrophobic interaction that drives enthalpic binding. The inhibition is competitive with respect to glutathione and can also reduce associated peroxidase activity in nuclear GSTs, while modestly affecting glyoxalase I activity.

What the Research Shows

Early work demonstrated that 0.2 mM S‑octylglutathione abolished the lag period of glutathione‑dependent protection against nuclear lipid peroxidation in isolated rat liver nuclei and reduced nuclear GST activity by >80 %. In canine erythrocytes, the compound inhibited GST activity without affecting glutathione reductase or peroxidase. It serves as a standard inhibitor in glyoxalase I assays, matching the potency of methotrexate. In vitro studies with quail and rabbit liver cytosol showed that S‑octylglutathione (80 % inhibition) blocks GST‑mediated biotransformation of the explosive CL‑20. Structural analyses with Schistosoma japonicum GST revealed asymmetric binding of S‑octylglutathione to one subunit of the dimer, while calorimetric data confirmed enthalpy‑driven binding and increasing affinity with longer alkyl chains.

Reported Benefits

Because it is a potent, well‑characterised GST inhibitor, S‑octylglutathione is valuable for dissecting the contribution of GSTs to detoxification pathways, lipid‑peroxidation protection, and xenobiotic metabolism in vitro. It provides a reliable benchmark for glyoxalase I inhibition assays and aids structural studies of GST‑ligand interactions, facilitating drug‑design efforts targeting these enzymes.

Limitations of the Evidence

All reported data are confined to isolated enzymes, cell‑free systems, or ex‑vivo tissue extracts; no in‑vivo efficacy, pharmacokinetic, or toxicity information is available. Inhibition potency varies among GST isoforms, and the compound also affects nuclear GST and glyoxalase I, limiting its selectivity. Consequently, its relevance to whole‑organism physiology remains uncertain.

Safety Considerations

The cited literature does not report adverse effects, but studies are limited to biochemical assays and isolated tissues. Inhibition of GSTs could theoretically impair cellular detoxification and antioxidant defenses if used in living systems. No regulatory approval exists, and safety in animals or humans has not been established.

How It Is Administered

S‑octylglutathione is employed in cell‑culture media and in vitro enzyme assays. In animal experiments it has been delivered intraperitoneally or intravenously, typically dissolved in an appropriate aqueous or buffered solution. Formulation details are not specified in the literature.

Routes of Administration

Goals & Uses

• Antiproliferative / anticancer activityOncology / ResearchLow
• Protein farnesyltransferase inhibitionEnzyme Inhibition / ResearchModerate
• Glyoxalase I inhibitionEnzyme Inhibition / Biochemical ToolHigh
• Glutathione S-transferase inhibitionEnzyme Inhibition / ResearchModerate
• Intracellular glutathione supplementation modelRedox Biology / ResearchModerate

Contraindications

• Human/clinical useRegulatory / SafetyHigh

Adverse Effects

• Cytotoxicity at high concentrationsIn Vitro ToxicityCommon
• Oxidative stress perturbationRedox DisruptionUnknown

Drug Interactions

No drug interactions recorded yet.

Population Constraints

• All human populationsGeneralAbsolute

Regulatory Status

• European UnionUnapprovedNo marketing authorization; used solely in laboratory research.
• United StatesUnapprovedInvestigational reagent, not approved for clinical use.
• United KingdomUnapprovedNo regulatory approval; research use only.

Not approved by any regulatory agency for clinical use. Used exclusively as a biochemical research reagent. Not classified as an investigational new drug (IND) in any known regulatory jurisdiction.

Evidence & Sources

• Role of a partially purified glutathione S-transferase from rat liver nuclei in the inhibition of nuclear lipid peroxidation
  Journal ArticleLowTirmenstein MA, Reed DJ1989-01-01T00:00:00.000000Z
• Effects of phenol compounds, glutathione analogues and a diuretic drug on glutathione S-transferase, glutathione reductase and glutathione peroxidase from canine erythrocytes
  Journal ArticleLowKurata M, Suzuki M, Takeda K1992-01-01T00:00:00.000000Z
• Inhibition of glyoxalase I by various clinically used anticancer drugs
  Journal ArticleLowKraus JL, Pernice P, Ponce C1988-01-01T00:00:00.000000Z
• In vitro degradation of hexanitrohexaazaisowurtzitane (CL-20) by cytosolic enzymes of Japanese quail and the rabbit
  Journal ArticleLowBardai GK, et al.2006-01-01T00:00:00.000000Z
• Crystallographic and thermodynamic analysis of the binding of S-octylglutathione to the Tyr 7 to Phe mutant of glutathione S-transferase from Schistosoma japonicum
  Journal ArticleLowAndújar-Sánchez M, et al.2005-01-01T00:00:00.000000Z
• A calorimetric study of the binding of S-alkylglutathiones to glutathione S-transferase
  Journal ArticleLowOrtiz-Salmerón E, et al.2001-01-01T00:00:00.000000Z

Frequently Asked Questions